Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00461045 · OUTCOME

Number of Patients Receiving Marizomib (MRZ) in Each Cycle

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma · Source last updated 2017-12-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Through study completion, an average of 6.09 weeks.

What was measured

A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle.

Groups in this outcome

MRZ 0.5 mg/m^2

Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MRZ 0.5 mg/m^215

Reported measurements

Cycle 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MRZ 0.5 mg/m^215Not reportedNot reportedNot reportedNot reported
Cycle 2
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MRZ 0.5 mg/m^212Not reportedNot reportedNot reportedNot reported
Cycle 3
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MRZ 0.5 mg/m^26Not reportedNot reportedNot reportedNot reported
Cycle 4
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MRZ 0.5 mg/m^23Not reportedNot reportedNot reportedNot reported
Cycle 5
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MRZ 0.5 mg/m^22Not reportedNot reportedNot reportedNot reported
Cycle 6
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MRZ 0.5 mg/m^21Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        15
    title
    Cycle 1
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        12
    title
    Cycle 2
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Cycle 3
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Cycle 4
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Cycle 5
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Cycle 6
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle.
groups
  1. description
    Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
    id
    OG000
    title
    MRZ 0.5 mg/m^2
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Through study completion, an average of 6.09 weeks.
title
Number of Patients Receiving Marizomib (MRZ) in Each Cycle
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice